TP53 and central nervous system cancer: It was found that there was the percentage of approximately 45.14% (265/587) glioma patients who displayed top 20 mutations of FRGs, with TP53 having the highest mutation frequency (42%) and 19 other FRGs with the mutation frequency range from 0% to 2% (Figure 2C).